Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modify…

Lumbar Spinal StenosisCardiac AmyloidosisATTR Amyloidosis Wild Type+3 more

~Estimated

~$10 – $750

Columbia UniversityNCT06034405

Phase 3

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

~Estimated

~$10 – $8,750

Intellia TherapeuticsNCT06128629

Myocardial & Hepatic Shear Wave Velocity Measurements in Patients With Non-Reduced-Ejection Fraction Heart Failure and Control Subjects - US Benchmarking Clinical Study

The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failu…

HFpEF - Heart Failure With Preserved Ejection FractionHFmrEFATTR-CM (Transthyretin Amyloid Cardiomyopathy)+2 more

~Estimated

~$10 – $1,125

eMyosound SASNCT07215715

Phase 3

An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]…

Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis

~Estimated

~$10 – $8,750

Life Molecular Imaging GmbHNCT05184088

← PreviousPage 2 of 2Next →